Skip to main content
Monthly Archives

September 2016

The UCI Consent 2 Contact Registry

By In the News
Research is the key to finding treatments and cures for Alzheimer’s disease and other urgent health problems. If you or someone you know is interested in helping researchers at UCI find cures faster, check out our new online potential participant registry, Consent 2 Contact (C2C)!  c2c.uci.edu    
Read More

Investigational antibody treatment yields exciting though preliminary results

By In the News
September 1, 2016 Nature   A paper published August 31 in Nature, describes that Biogen Idec’s candidate treatment, aducanumab, reduced amyloid-β in the brains of patients with early-stage Alzheimer’s disease. Patients receiving the highest doses of the medicine in the Phase IB trial had the largest reductions in brain amyloid and also declined the least in clinical assessments.  These are promising results that will require replication in larger clinical trials, which have recently launched, including at UCI MIND. Read the Nature news article about the study here.
Read More